Rep. Marjorie Taylor Greene Buys Merck & Co., Inc. (NYSE:MRK) Stock

Posted by Renee Jackson on May 8th, 2025

Representative Marjorie Taylor Greene (R-Georgia) recently bought shares of Merck & Co., Inc. (NYSE:MRK). In a filing disclosed on May 06th, the Representative disclosed that they had bought between $1,001 and $15,000 in Merck & Co., Inc. stock on May 5th. The trade occurred in the Representative’s “MARJORIE IRA” account.

Representative Marjorie Taylor Greene also recently made the following trade(s):

Purchased $1,001 – $15,000 in shares of AbbVie (NYSE:ABBV) on 5/5/2025.
Purchased $1,001 – $15,000 in shares of Occidental Petroleum (NYSE:OXY) on 5/5/2025.
Purchased $1,001 – $15,000 in shares of Paychex (NASDAQ:PAYX) on 5/5/2025.
Purchased $1,001 – $15,000 in shares of MercadoLibre (NASDAQ:MELI) on 5/5/2025.
Purchased $1,001 – $15,000 in shares of Starbucks (NASDAQ:SBUX) on 5/5/2025.
Purchased $1,001 – $15,000 in shares of BP (NYSE:BP) on 5/5/2025.
Purchased $1,001 – $15,000 in shares of Gilead Sciences (NASDAQ:GILD) on 5/5/2025.
Purchased $1,001 – $15,000 in shares of BHP Group (NYSE:BHP) on 5/5/2025.
Purchased $1,001 – $15,000 in shares of Advanced Micro Devices (NASDAQ:AMD) on 5/5/2025.
Purchased $1,001 – $15,000 in shares of Alphabet (NASDAQ:GOOG) on 5/5/2025.

Merck & Co., Inc. Stock Up 0.1 %

Shares of MRK stock opened at $79.09 on Thursday. Merck & Co., Inc. has a 12 month low of $75.93 and a 12 month high of $134.63. The company has a 50 day simple moving average of $85.91 and a two-hundred day simple moving average of $93.72. The company has a current ratio of 1.36, a quick ratio of 1.15 and a debt-to-equity ratio of 0.79. The stock has a market cap of $198.60 billion, a P/E ratio of 11.75, a P/E/G ratio of 0.77 and a beta of 0.43.

Merck & Co., Inc. (NYSE:MRK – Get Free Report) last released its quarterly earnings results on Thursday, April 24th. The company reported $2.22 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.16 by $0.06. Merck & Co., Inc. had a return on equity of 45.35% and a net margin of 26.67%. The business had revenue of $15.53 billion during the quarter, compared to analyst estimates of $15.59 billion. During the same quarter in the previous year, the company posted $2.07 earnings per share. Merck & Co., Inc.’s revenue for the quarter was down 1.6% on a year-over-year basis. On average, research analysts expect that Merck & Co., Inc. will post 9.01 earnings per share for the current year.

Merck & Co., Inc. declared that its board has initiated a share repurchase program on Tuesday, January 28th that allows the company to repurchase $10.00 billion in outstanding shares. This repurchase authorization allows the company to buy up to 4.1% of its shares through open market purchases. Shares repurchase programs are typically an indication that the company’s management believes its stock is undervalued.

Insider Buying and Selling at Merck & Co., Inc.

In related news, SVP Dalton E. Smart III sold 4,262 shares of the business’s stock in a transaction that occurred on Friday, April 25th. The shares were sold at an average price of $82.76, for a total transaction of $352,723.12. Following the completion of the transaction, the senior vice president now owns 7,778 shares in the company, valued at $643,707.28. The trade was a 35.40 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Insiders own 0.13% of the company’s stock.

Institutional Trading of Merck & Co., Inc.

Hedge funds have recently added to or reduced their stakes in the business. Midwest Capital Advisors LLC bought a new position in Merck & Co., Inc. in the fourth quarter worth approximately $26,000. Barnes Dennig Private Wealth Management LLC purchased a new stake in shares of Merck & Co., Inc. during the 1st quarter worth $27,000. Financial Life Planners bought a new stake in Merck & Co., Inc. during the fourth quarter valued at about $28,000. Noble Wealth Management PBC purchased a new position in Merck & Co., Inc. in the fourth quarter valued at about $28,000. Finally, Halbert Hargrove Global Advisors LLC bought a new position in Merck & Co., Inc. in the fourth quarter worth about $28,000. 76.07% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several research firms recently issued reports on MRK. TD Securities lowered shares of Merck & Co., Inc. from a “buy” rating to a “hold” rating and reduced their target price for the stock from $121.00 to $100.00 in a report on Monday, February 10th. Truist Financial restated a “hold” rating and set a $110.00 price objective (down from $130.00) on shares of Merck & Co., Inc. in a research report on Wednesday, January 8th. Bank of America dropped their target price on shares of Merck & Co., Inc. from $118.00 to $112.00 and set a “buy” rating for the company in a report on Wednesday, February 5th. Deutsche Bank Aktiengesellschaft cut Merck & Co., Inc. from a “buy” rating to a “hold” rating and decreased their price target for the company from $128.00 to $105.00 in a report on Tuesday, February 18th. Finally, TD Cowen lowered Merck & Co., Inc. from a “buy” rating to a “hold” rating and dropped their price objective for the stock from $121.00 to $100.00 in a research note on Monday, February 10th. Twelve research analysts have rated the stock with a hold rating, eight have assigned a buy rating and three have given a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $111.13.

Read Our Latest Report on MRK

About Representative Greene

Marjorie Taylor Greene (Republican Party) is a member of the U.S. House, representing Georgia’s 14th Congressional District. She assumed office on January 3, 2021. Her current term ends on January 3, 2027.

Greene (Republican Party) is running for re-election to the U.S. House to represent Georgia’s 14th Congressional District. She declared candidacy for the 2026 election.

About Merck & Co., Inc.

(Get Free Report)

Merck & Co, Inc is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products.